PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
HOTH Hoth Therapeutics
- 1.1300
- +0.0600+5.61%
Close Feb 14 16:00 ET
- 1.1498
- +0.0198+1.75%
Post 19:59 ET
14.86MMarket Cap-0.89P/E (TTM)
1.1500High1.0800Low301.71KVolume1.1000Open1.0700Pre Close335.16KTurnover2.31%Turnover RatioLossP/E (Static)13.15MShares3.800052wk High1.98P/B14.78MFloat Cap0.580052wk Low--Dividend TTM13.08MShs Float347.0000Historical High--Div YieldTTM6.54%Amplitude0.5800Historical Low1.1100Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
Hoth Therapeutics Stock Forum
HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research
PR Newswire· 1 min ago
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study...
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Monday, 10th February at 8:22 am
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemi...
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
Friday, 24th January at 8:29 am
NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requireme...
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
Tuesday, 21st January at 8:29 am
IP will be used to pursue further indications for HT-001 Cancer Therapeutic
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications ...
ahem
No comment yet